中国癌症杂志 ›› 2022, Vol. 32 ›› Issue (11): 1074-1083.doi: 10.19401/j.cnki.1007-3639.2022.11.005

• 论著 • 上一篇    下一篇

血浆外泌体中的CD48蛋白作为潜在的肝细胞癌诊断标志物的研究

成意财1,2(), 杜振华3, 范志娟4, 冯岚2, 曹鹏博2, 周钢桥1,2()   

  1. 1.南华大学衡阳医学院,湖南 衡阳 421000
    2.军事科学院军事医学研究院辐射医学研究所,蛋白质组学国家重点实验室,国家蛋白质科学中心,北京 100850
    3.天津市武警特色医学中心检验科,天津 300160
    4.天津市第三中心医院医学重点学科(专科),天津 300170
  • 收稿日期:2022-02-15 修回日期:2022-04-30 出版日期:2022-11-30 发布日期:2022-12-14
  • 通信作者: 周钢桥
  • 作者简介:成意财(ORCID: 0000-0002-2209-1180),硕士。
  • 基金资助:
    国家传染病科技重大专项课题(2018ZX10732202);国家传染病科技重大专项课题(2017ZX10203205)

Plasma exosomal CD48 protein as a candidate diagnostic biomarker for hepatocellular carcinoma

CHENG Yicai1,2(), DU Zhenhua3, FAN Zhijuan4, FENG Lan2, CAO Pengbo2, ZHOU Gangqiao1,2()   

  1. 1. Hengyang Medical School, University of South China, Hengyang 421000, Hunan Province, China
    2. State Key Lab of Proteomics, National Center for Protein Sciences at Beijing, Institute of Radiation Medicine, Academy of Military Medical Sciences, Academy of Military Sciences, Beijing 100850, China
    3. Laboratory Department of Tianjin Armed Police Characteristic Medical Center, Tianjin 300160, China
    4. Medical Key Disciplines of the Third Central Hospital of Tianjin (Specialist), Tianjin 300170, China
  • Received:2022-02-15 Revised:2022-04-30 Published:2022-11-30 Online:2022-12-14
  • Contact: ZHOU Gangqiao

摘要:

背景与目的:约60%的肝细胞癌(hepatocellular carcinoma,HCC)患者在晚期才被确诊,因而无法得到及时有效的治疗,目前临床上常用于HCC诊断的血清标志物的灵敏度均偏低。本研究通过分析血浆外泌体蛋白质组的表达差异,鉴定可能用于HCC诊断的候选外泌体蛋白质标志物。方法:首先,采用鸟枪法蛋白质组质谱分析方法,对发掘人群[包括4名健康对照者(healthy control,HC)组和4例HCC患者组]的血浆外泌体进行全蛋白质组的定性和定量分析,并筛选差异表达蛋白质。然后,采用酶联免疫吸附试验(enzyme-linked immunosorbent assay,ELISA)在独立的验证人群[包括56例HCC患者组、20例肝硬化(liver cirrhosis,LC)患者组和48名HC组]中进行验证实验,并评估候选蛋白质分子在HCC诊断中的潜在价值。结果:在发掘人群中,共鉴定到1 434种血浆外泌体蛋白质,其中的CD48蛋白在HCC患者中的表达水平显著高于HC组个体。进一步采用ELISA在独立验证人群中证实CD48蛋白在HCC患者中的表达水平显著高于LC和HC个体,受试者工作特征(receiver operating characteristic,ROC)曲线的曲线下面积(area under curve,AUC)为0.886。当联合检测血浆外泌体中的CD48蛋白和血浆中的甲胎蛋白(alpha-fetoprotein,AFP)时,AUC可提升至0.970。结论:血浆外泌体中的CD48蛋白可能作为HCC的候选诊断标志物,当其与AFP联合应用时可能进一步提高HCC的临床诊断能力。

关键词: 肝细胞癌, 外泌体, 蛋白质组, 诊断标志物, CD48

Abstract:

Background and purpose: Approximately 60% of patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage, therefore cannot receive timely and effective treatment. At present, the sensitivity of serum biomarkers commonly used in the diagnosis of HCC is low. In this paper, through the differential expression analysis of plasma exosomal proteome, the candidate exosome protein markers which may be used in the diagnosis of HCC were identified. Methods: First, we performed shot-gun proteome mass spectrometry assays in the plasma exosomes from the discovery cohort [including 4 healthy control (HC) group and 4 HCC patients group], and identified differentially expressed proteins by qualitative and quantitative analyses. Then, we carried out enzyme-linked immunosorbent assay (ELISA) in plasma samples of an independent verification cohort [including 56 HCC patients group, 20 liver cirrhosis (LC) patients group and 48 HC group], and evaluated the diagnostic value of the candidate protein in HCC. Results: In the discovery cohort, we identified a total of 1 434 exosomal proteins, of which CD48 exhibited higher levels in HCC than in HC. We further verified in the validation cohort by ELISA that CD48 was markedly higher in HCC compared with LC and HC groups, with the area under receiver operating characteristic (ROC) curve (AUC) of 0.886. When combined with plasma alpha-fetoprotein (AFP), the AUC reached 0.970. Conclusion: The plasma exosomal CD48 protein can be used as a candidate diagnostic biomarker for HCC, and its combination with AFP may further improve the clinical diagnostic ability for HCC.

Key words: Hepatocellular carcinoma, Exosome, Proteome, Diagnostic biomarker, CD48

中图分类号: